Ruijin Hospital: Lymphoma trials

The registry lists 84 Lymphoma studies with Ruijin Hospital as lead sponsor. 54 are open to participants now and 0 have results posted.

Phase 1 6Phase 2 35Phase 3 10Phase 4 5No phase 32(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Exploration of Circular RNA in B-cell Hematologic MalignanciesRecruitingNCT07774572Phase 1
• Shanghai Lymphoma Clinical CohortNot yet recruitingNCT07285174
• A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell LymphomaNot yet recruitingNCT06963632
• Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell LymphomaNot yet recruitingNCT06935136Not applicable
• Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell LymphomaRecruitingNCT06876688Phase 2
• The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell LymphomaNot yet recruitingNCT06863441
• Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism LymphomaRecruitingNCT06795113
• Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory LymphomaNot yet recruitingNCT06788600
• PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell LymphomaRecruitingNCT06755775
• Dynamic CtDNA-guided Targeted Therapy in DLBCLNot yet recruitingNCT06748521Phase 2
• The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical StudyNot yet recruitingNCT06747299
• Go-CHOP in de Novo Intestinal T-cell Lymphoma PatientsNot yet recruitingNCT06701344Phase 2
• Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial RemissionNot yet recruitingNCT06669143Phase 2
• The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter StudyNot yet recruitingNCT06656234
• A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell LymphomaNot yet recruitingNCT06656221Phase 2
• Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor LymphomaNot yet recruitingNCT06652152
• Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC PositiveNot yet recruitingNCT06652139Phase 2
• Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCLNot yet recruitingNCT06573151Phase 2
• Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCLNot yet recruitingNCT06573138Phase 2
• A Real-World Study on Extranodal LymphomaNot yet recruitingNCT06573099
• CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic FactorsNot yet recruitingNCT06567366Phase 2
• Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)Not yet recruitingNCT06549335Phase 2
• Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data CollectionRecruitingNCT06541327
• Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)RecruitingNCT06534463
• The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRecruitingNCT06522555Phase 3
• Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentRecruitingNCT06496308Phase 3
• A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell LymphomaRecruitingNCT06494371Phase 1
• Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingNCT06441097Phase 2
• The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell LymphomaNot yet recruitingNCT06255795Phase 3
• A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell LymphomaRecruitingNCT06136351Phase 2
• Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCLNot yet recruitingNCT06062641Phase 2
• Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational ResearchNot yet recruitingNCT06049381
• Real-World Study of DLBCL With Different Genetic SubtypesRecruitingNCT06026488
• Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)RecruitingNCT05934864
• Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System InvolvementRecruitingNCT05926427Phase 2
• Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell LymphomaNot yet recruitingNCT05923879
• (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)Not yet recruitingNCT05923502
• A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological TypesNot yet recruitingNCT05907447
• A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FLRecruitingNCT05899621
• A Combination Study of CAR-T Therapy in r/r B-NHLRecruitingNCT05871684Phase 2
• Real World Study of Linperlisib for Lymphoma TreatmentNot yet recruitingNCT05863871
• Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCLNot yet recruitingNCT05863845Not applicable
• A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin LymphomaRecruitingNCT05852028
• Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell LymphomaRecruitingNCT05806580Phase 4
• Genotype-guided Treatment in Newly Diagnosed PTCLRecruitingNCT05675813Phase 1/2
• PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell LymphomaRecruitingNCT05662540Not applicable
• A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingNCT05559008Phase 1/2
• Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell LymphomaRecruitingNCT05367856Phase 2
• Genotype-guided Treatment in DLBCLRecruitingNCT05351346Phase 3
• Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
• Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System LymphomaRecruitingNCT05334238Phase 3
• The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 YearsRecruitingNCT05179733Phase 3
• Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical StudyRecruitingNCT04880746Phase 3
• Cell Free DNA in Mature B-cell LymphomaRecruitingNCT04088422
• A Retrospective Study on Extranodal DLBCLCompletedNCT06549361
• Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell LymphomaStatus unknownNCT05189782
• Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical StudyStatus unknownNCT04842318Phase 4
• Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCLStatus unknownNCT04705129Phase 2
• Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNAStatus unknownNCT04539119Phase 3
• Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional ChemotherapyStatus unknownNCT04480125Phase 2
• Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell LymphomaActive, not recruitingNCT04480099Phase 2
• Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04460248Phase 2
• Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's LymphomasStatus unknownNCT04435743
• A Single-cell Transcriptome Study in Patients With Non-Hodgkin's LymphomaStatus unknownNCT04434833
• Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell LymphomaStatus unknownNCT04096690Phase 2
• Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in LymphomaStatus unknownNCT04083079Phase 4
• A Registry Study in Lymphoma Patients Treated With Liposomal DoxorubicinStatus unknownNCT04069845
• Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCLStatus unknownNCT03949062Phase 2
• A Metagenome-wide Association Study of Gut Microbiota in Gastrointestinal Non-Hodgkin's Lymphoma PatientsStatus unknownNCT03930043
• Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell LymphomaStatus unknownNCT03853044Phase 2
• R2 in the Treatment of Follicular LymphomaStatus unknownNCT03715309Phase 2
• Lenalidomide Based Immunotherapy in the Treatment of DLBCLStatus unknownNCT03715296
• A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma PatientsStatus unknownNCT03600363Phase 2
• Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory LymphomaStatus unknownNCT03468153Phase 1/2
• Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCLStatus unknownNCT03367143Phase 2
• Decitabine Plus R-CHOP in Diffuse Large B-cell LymphomaStatus unknownNCT02951728Phase 1/2
• Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell LymphomaCompletedNCT02825147Phase 2
• Chidamide Plus R-CHOP in Elderly DLBCLStatus unknownNCT02753647Phase 2
• Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell LymphomaStatus unknownNCT02753543Phase 2
• Reduced Chemotherapy in Low Risk DLBCLStatus unknownNCT02752815Phase 4
• MESA Versus ESA in the Treatment of Early Stage NK/T-cell LymphomaStatus unknownNCT02631239Phase 3
• A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCLStatus unknownNCT02542111Phase 2
• R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3BStatus unknownNCT01852435Phase 3
• CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell LymphomaStatus unknownNCT01746992Phase 4